TECNIC's solution for revolutionizing Cell Therapy

In the landscape of biotechnology, significant strides are being made in next-generation cell and gene therapies (CGTs) ā‡€, presenting a groundbreaking avenue for unprecedented curative interventions in patients with limited therapeutic options for specific medical conditions by providing personalized and targeted approaches

This new technology, called cell therapy, focuses on the introduction of new, healthy cells into the body with the goal of replacing diseased or damaged ones, modulating the function of the patientā€™s cells through the expression of factors, or encompassing the removal of dysfunctional cells using immune cells. The potential of cell therapy to halt and reverse diseases, restore damaged organs, and ultimately cure life-threatening conditions is now a realistic goal for scientists who operate at the forefront of regenerative medicine. However, there are immediate and long-term challenges that can be a problem during the manufacturing processes of these medical therapeutics.

In response, TECNIC upstream scalable cell expansion bioreactors and downstream processing portfolio of technologies play a pivotal role in supporting cell expansion, harvest, wash, and concentration, always helping you achieve the desired production from scales of Clinical Research to Pilot and Industrial Bioprocesses ā‡€.

What is cell therapy?

From the perspective of life development, diseases in a living body usually indicate problems in the basic unit of its life: cells. In this sense, cell therapy is a broad term that encompasses the use and differentiation of various cell types, typically multipotent cells, as a therapeutic application that provides remarkable outcomes for patients in need of new treatment options. The primary aim of this type of biotherapy is to develop medicinal products and therapeutic strategies to repair and stimulate damaged tissue and organs or, furthermore, cure diseases and conditions such as lung diseases, neurodegenerative disorders, autoimmune diseases and cancers like adult-onset leukaemia, Hodgkin's lymphoma, or acute myeloblastic leukaemia (AML)

A prime example of its application is the use of induced pluripotent stem cells (iPSC cells) to provide an unlimited T cell source for CAR T cell therapy development, which involves reprogramming the patientā€™s T-cells to target and destroy specific cancer antigens. This combination of iPSC and CAR technologies provides an extraordinary opportunity to oncology and greatly accelerates the development of cell-based therapy for cancer patients.

The advantage of this biotherapy is that it can be personalized to cure specific individual pathologies. Also, following the principle ā€œPrimum non nocereā€ (first do no harm) and taking into consideration that cellular repair occurs naturally in the human body, cellular therapy is considered to be safe, with no or few adverse effects observed in numerous animal and human preclinical and clinical studies.

Cell therapies and the evolving role of personalized medicine

Personalized medicine is an innovative approach to disease prevention and treatment that takes into account differences in how individuals respond to medication in order to provide ā€œthe right therapy at the right dose at the right timeā€. After being approved in medical trials, the advances made in personalized medicine have already led to powerful new discoveries and approved treatments that are tailored to the specific characteristics of individuals.

Within this paradigm, allogenic and autologous cell therapies emerge as promising avenues:

Autologous cell therapy

Allogenic cell therapy

Scale-up vs Scale-out approaches

Challenges in cell therapy

Cell therapies are actively being developed and hold great promise to treat a multitude of disease indications. However, there are immediate and long-term challenges to overcome that create obstacles during the manufacturing process of these therapeutics:

Manufacture challenges

Scalability challenges

Cost of manufacture challenges

Advanced Bioreactors

In response to these challenges, TECNIC has developed automatic bioprocess equipment for both upstream and downstream development. We understand that, unlike traditional biotech manufacture (like mAbs and other biologics), the production and processing of this therapies requires that the cellular material retains the critical quality attributes (CQAs) thought the entire process.

For that reason, TECNIC eLABĀ® ā‡€ , ePILOTĀ® ā‡€ and ePRODĀ® ā‡€ bioreactors are designed to ensure high-quality and reproducible results to overcome the previously mentioned challenges. We offer the best bioprocess solution for cell therapies, as our equipment is meticulously designed to provide precise control over environmental parameters, optimizing cellular conditions for maximal yield while minimizing resources and time utilization. Furthermore, our equipment is designed with an automatic unit control that includes integrated data analytics systems, which enables you to fine-tune the culture conditions to develop a smooth bioprocess performance.

Advanced Bioreactor Solutions ā‡€

Tangential Flow Filtration in cell therapy

Most of the research and development bioprocesses of cell and gene therapies (CGTs) has focused on the intensification of the upstream process. Whilst R&D should continue focusing on improving cell density and other cellular expansion needs, the manufacturing bottleneck is inevitably leaning towards the downstream processing. In order to address this need with high specificity and high throughput, our eLABĀ® TFF ā‡€, eLABĀ® TFF SU ā‡€, ePILOTĀ® TFF ā‡€ and ePRODĀ® TFF ā‡€ offer a solution that can be scaled, automated, fully contained and amenable to process development activities. Whether you are engaged in pioneering research or driving industrial-scale production, enable us to meet your end demand to develop your cell therapies projects.

To ensure that advances in upstream processing are maximized, TECNIC equipment also ensures an effective downstream process development for volume reduction, wash and formulation of the final product. At the same time, the automation of our equipment recipes significantly minimizes the need for manual adjustments, enhancing user performance and reducing labor costs. Furthermore, we enable you to have high protein clearance, high recovery of viable cells with minimal impact on its viability.

Advanced Tangential Flow Filtration Solutions ā‡€

Success stories and applications

Given the complexity of the bioprocess, it comes as a no surprise the notoriously expensive cost of these biotherapies. In TECNIC we want to help our clients to make therapy cell more scalable and, therefore, more accessible to patients. As with any new technology, the cost come down over time with the best innovation and, while we cannot provide specific details due to confidentiality, there have been numerous instances where TECNIC's equipment has significantly enhanced the production these therapies.

With our fully automatic bioreactor eLABĀ® Advanced and thanks to its multiple configuration (up to 12 fully independent vessels), one of our clients is doing groundbreaking development of autologous cell therapy for replace damaged bone marrow after decorative cancer treatments. Knowing that, as with any form of cell therapy, the end-product quality and quantity depend on the initial population of T cells activated and expanded ex vivo, this specific client had two big important requirements:

Because the imperious need of compatibly, every patient T cells activated to trigger ex vivo expansion required from a unique bioreactor culture.

Also, because their usually patient is severely ill, their T cells are typically mature, differentiated and may have stunted grow rates, so our client needed to be able to expand the cell in very strict culture conditions.

In order to satisfy these two points, we recommended our client the eLABĀ® Advanced ā‡€. Thanks to this equipment, designed with versatility in mind, our bioreactor empowered them to development with high precision and control a large range of different T cells cultures of their patients, enabling them to fine-tune their culture conditions using an automatic control unit controlled with an industrial PLC. With it, they were able to have full control over crucial parameters ā€“ such as temperature, pH, dissolved oxygen, and agitation speed ā€“ of up to 12 fully independent patient cultures simultaneously with reliability and efficiency.

This same client, seeing the previous good results with TECNIC equipment and assistance, decided to scale-up one of their previous working lines with allogenic therapies, which were manufactured in large batches from unrelated donor tissues such as bone marrow. In order to make the allogenic cell therapy more accessible to patients, their logistics and cost studies demanded an automatic production in cultures of 50 L.

Ā 

Given the complexity of the bioprocess, it comes as a no surprise the notoriously expensive cost of these biotherapies. In TECNIC we want to help our clients to make therapy cell more scalable and, therefore, more accessible to patients. As with any new technology, the cost come down over time with the best innovation and, while we cannot provide specific details due to confidentiality, there have been numerous instances where TECNIC's equipment has significantly enhanced the production these therapies.

With our fully automatic bioreactor eLABĀ® Advanced and thanks to its multiple configuration (up to 12 fully independent vessels), one of our clients is doing groundbreaking development of autologous cell therapy for replace damaged bone marrow after decorative cancer treatments. Knowing that, as with any form of cell therapy, the end-product quality and quantity depend on the initial population of T cells activated and expanded ex vivo, this specific client had two big important requirements:

  • Because the imperious need of compatibly, every patient T cells activated to trigger ex vivo expansion required from a unique bioreactor culture.
  • Also, because their usually patient is severely ill, their T cells are typically mature, differentiated and may have stunted grow rates, so our client needed to be able to expand the cell in very strict culture conditions.

In order to satisfy these two points, we recommended our client the eLABĀ® Advanced ā‡€. Thanks to this equipment, designed with versatility in mind, our bioreactor empowered them to development with high precision and control a large range of different T cells cultures of their patients, enabling them to fine-tune their culture conditions using an automatic control unit controlled with an industrial PLC. With it, they were able to have full control over crucial parameters ā€“ such as temperature, pH, dissolved oxygen, and agitation speed ā€“ of up to 12 fully independent patient cultures simultaneously with reliability and efficiency.

This same client, seeing the previous good results with TECNIC equipment and assistance, decided to scale-up one of their previous working lines with allogenic therapies, which were manufactured in large batches from unrelated donor tissues such as bone marrow. In order to make the allogenic cell therapy more accessible to patients, their logistics and cost studies demanded an automatic production in cultures of 50 L.

Ā 

Explore our complete range of equipment

Our bioreactors are designed for diverse applications, ensuring efficiency and quality. Discover our full range of biotechnology solutions, including Bioreactors, Tangential Flow Filtration systems, and more. Visit our pages for Bioreactors ā‡€, Tangential Flow Filtration ā‡€, and Contact ā‡€ for further information and inquiries.

Our advanced bioprocess equipment ā‡€